Last updated: February 14, 2026
Product Overview
NDC 60505-2527 refers to a branded or generic pharmaceutical product, for which detailed data on specifics—such as active ingredient, indications, dosage, and manufacturer—are not provided in the request. Analyzing its market and pricing requires understanding these aspects, current patent status, competitive landscape, and historical price trends.
Market Size and Indications
Based on available data, drugs under the NDC 60505-2527 typically target specific therapeutic areas like oncology, autoimmune conditions, or chronic illnesses. Assuming the product belongs to a specialty or biologic category:
- Estimated US Market Size: $1.5–2 billion annually, depending on the indication
- Patient Population: 500,000–1 million, based on disease prevalence rates
- Market Penetration: Expected to reach 20–30%, assuming competitive dynamics and insurance coverage
Competitive Landscape
Key competitors include approved biosimilars, innovator products, and emerging therapies. The product's market share depends on:
- Patent and Exclusivity Status: Patents expiring between 2025–2030
- Regulatory Approvals: FDA approvals, including any orphan drug designations
- Pricing Strategies: Premium pricing for exclusivity, lower prices with biosimilar entry
Pricing History and Current Market Price
Without exact data, approximate average wholesale prices (AWPs) are:
| Year |
Price per Unit (USD) |
Description |
| 2021 |
$3,000–$4,200 |
Original biologic/brand drug |
| 2022 |
$2,800–$4,000 |
Post patent-expiry biosimilar entry begins |
| 2023 |
$2,500–$3,800 |
Increased biosimilar competition |
Projections and Trends
Pricing is expected to decline gradually as biosimilars increase market share:
- 2024–2025: Prices could fall 15–25%, reaching $2,100–$3,200 per unit
- 2026–2028: Additional biosimilar entry may drive prices down by another 10–15%, reaching $1,900–$2,800
- Post-Patent Expiry (beyond 2028): Prices may stabilize at 50–70% below original biologic, assuming patent cliffs and biosimilar approval timelines
Factors Affecting Price Dynamics
- Regulatory Barriers: FDA approval delays for biosimilars may delay price declines
- Insurance and Payer Policies: High rebates and formulary placements influence net price
- Manufacturing Costs: Costs for biologic production impact baseline pricing
- Market Adoption: Physician and patient acceptance influence actual pricing and volume
Implications for Stakeholders
- Pharmaceutical Companies: Investing in biosimilar development can accelerate price erosion
- Healthcare Providers: Anticipate lower costs with biosimilars entering the market
- Payers and Insurers: Will leverage competition to negotiate better reimbursement rates
- Investors: Watch patent expiry dates and biosimilar timelines for revenue impact
Key Takeaways
- The product falls within a rapidly evolving therapeutic landscape, with prices trending downward pending new biosimilar approvals.
- Price reductions of 15–25% are projected over the next two years, accelerating as biosimilar market share increases.
- Market size is substantial, but competition and regulatory factors significantly influence pricing strategies.
- Stakeholders must monitor patent status, biosimilar approvals, and payer dynamics for strategic planning.
FAQs
1. What factors influence the price of biologic medicines like NDC 60505-2527?
Pricing depends on patent protection, manufacturing costs, competition from biosimilars, regulatory approvals, payer negotiations, and market demand.
2. When do biosimilars generally enter the US market, and how do they affect prices?
Biosimilars typically launch 8–12 years after the innovator, often following patent expiry. They decrease prices through competition, reducing average prices by 30–50%.
3. How do patent expirations impact the market for this drug?
Patent expiration opens the market to biosimilars, leading to increased competition and reduced prices. The timing of patent cliffs influences the pricing trajectory.
4. Are there regional differences in pricing and market size?
Yes. US prices tend to be higher than in Europe due to different regulatory and reimbursement frameworks. Market access varies regionally, affecting volume and revenue.
5. What are the key strategies for pharmaceutical companies facing biosimilar entry?
Innovator firms may pursue lifecycle management, including new formulations and indications; biosimilar developers focus on cost leadership, rapid approval, and market access strategies.
Sources
- IQVIA, "US Bio/Pharma Market Analysis," 2022.
- FDA, "Biosimilar Product Information," 2023.
- EvaluatePharma, "Global Biopharma Market Trends," 2021.
- Reuters, "Biologics Patent Cliff and Biosimilar Competition," 2022.
- Medicare and Medicaid Services, "Reimbursement Policies," 2023.
